Assessing the economic challenges posed by orphan drugs: a comment on Drummond et al

Int J Technol Assess Health Care. 2007 Summer;23(3):397-401; author reply 401-4. doi: 10.1017/s0266462307071012.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Cost-Benefit Analysis
  • Europe
  • Health Policy
  • Humans
  • Orphan Drug Production / economics*
  • Technology Assessment, Biomedical*
  • United States